Targeted Oncology1h
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The Armenian Reporter6h
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lessened by Quattro Financial Advisors LLC
Quattro Financial Advisors LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.7% during the ...
The Armenian Reporter9h
Avitas Wealth Management LLC Sells 18,936 Shares of AstraZeneca PLC (NASDAQ:AZN)
Avitas Wealth Management LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 39.2% in the ...
Antibody Drug Conjugates (ADC) Market To Hit USD 29.10 Billion By 2032, Driven By Rising Cancer Cases
Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...
oncnursingnews4h
T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.